224 related articles for article (PubMed ID: 24887419)
21. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
[TBL] [Abstract][Full Text] [Related]
22. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
23. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
24. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
26. Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.
Bratton MR; Martin EC; Elliott S; Rhodes LV; Collins-Burow BM; McLachlan JA; Wiese TE; Boue SM; Burow ME
J Steroid Biochem Mol Biol; 2015 Jun; 150():17-23. PubMed ID: 25771071
[TBL] [Abstract][Full Text] [Related]
27. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
28. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
[TBL] [Abstract][Full Text] [Related]
29. PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Citro S; Miccolo C; Meloni L; Chiocca S
J Mol Cell Biol; 2015 Apr; 7(2):132-42. PubMed ID: 25801958
[TBL] [Abstract][Full Text] [Related]
30. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
31. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
32. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
[TBL] [Abstract][Full Text] [Related]
33. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
34. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
[TBL] [Abstract][Full Text] [Related]
35. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.
Kok M; Holm-Wigerup C; Hauptmann M; Michalides R; Stål O; Linn S; Landberg G
J Natl Cancer Inst; 2009 Dec; 101(24):1725-9. PubMed ID: 19940281
[TBL] [Abstract][Full Text] [Related]
37. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
Bentin Toaldo C; Alexi X; Beelen K; Kok M; Hauptmann M; Jansen M; Berns E; Neefjes J; Linn S; Michalides R; Zwart W
BMC Cancer; 2015 Aug; 15():588. PubMed ID: 26272591
[TBL] [Abstract][Full Text] [Related]
38. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
